Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Sales (2022 - 2026)

Axsome Therapeutics' Return on Sales history spans 5 years, with the latest figure at 0.0% for Q1 2026.

  • On a quarterly basis, Return on Sales changed 0.0% to 0.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.0%, a 1.0% increase, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Sales hit 0.0% in Q1 2026 for Axsome Therapeutics, down from 0.0% in the prior quarter.
  • Over the last five years, Return on Sales for AXSM hit a ceiling of 0.0% in Q1 2023 and a floor of 1.5% in Q4 2024.
  • Historically, Return on Sales has averaged 0.1% across 5 years, with a median of 0.01% in 2024.
  • Biggest five-year swings in Return on Sales: tumbled -148bps in 2024 and later surged 150bps in 2025.
  • Tracing AXSM's Return on Sales over 5 years: stood at 0.03% in 2022, then skyrocketed by 45bps to 0.01% in 2023, then crashed by -10763bps to 1.5% in 2024, then surged by 100bps to 0.0% in 2025, then crashed by -131bps to 0.0% in 2026.
  • Business Quant data shows Return on Sales for AXSM at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.